CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations.

IF 2.5 2区哲学 Q1 ETHICS

Journal of Law and the Biosciences Pub Date : 2024-01-26 eCollection Date: 2024-01-01 DOI:10.1093/jlb/lsad030

Danielle M Pacia, Beatrice L Brown, Timo Minssen, Jonathan J Darrow

引用次数: 0

查看原文本刊更多论文

应对抗生素耐药性危机的 CRISPR-噬菌体抗菌剂：科学、经济和监管方面的考虑因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Law and the Biosciences Medicine-Medicine (miscellaneous)

CiteScore

7.40

自引率

5.90%

发文量

审稿时长

13 weeks

期刊介绍： The Journal of Law and the Biosciences (JLB) is the first fully Open Access peer-reviewed legal journal focused on the advances at the intersection of law and the biosciences. A co-venture between Duke University, Harvard University Law School, and Stanford University, and published by Oxford University Press, this open access, online, and interdisciplinary academic journal publishes cutting-edge scholarship in this important new field. The Journal contains original and response articles, essays, and commentaries on a wide range of topics, including bioethics, neuroethics, genetics, reproductive technologies, stem cells, enhancement, patent law, and food and drug regulation. JLB is published as one volume with three issues per year with new articles posted online on an ongoing basis.